Pharmacological Research (Oct 2023)

Pillars of long-term antiretroviral therapy success

  • Lucia Taramasso,
  • Massimo Andreoni,
  • Andrea Antinori,
  • Alessandra Bandera,
  • Paolo Bonfanti,
  • Stefano Bonora,
  • Marco Borderi,
  • Antonella Castagna,
  • Anna Maria Cattelan,
  • Benedetto Maurizio Celesia,
  • Stefania Cicalini,
  • Antonella Cingolani,
  • Andrea Cossarizza,
  • Antonella D'Arminio Monforte,
  • Gabriella D'Ettorre,
  • Antonio Di Biagio,
  • Simona Di Giambenedetto,
  • Giovanni Di Perri,
  • Vincenzo Esposito,
  • Emanuele Focà,
  • Cristina Gervasoni,
  • Andrea Gori,
  • Nicola Gianotti,
  • Giovanni Guaraldi,
  • Roberto Gulminetti,
  • Sergio Lo Caputo,
  • Giordano Madeddu,
  • Paolo Maggi,
  • Giorgio Marandola,
  • Giulia Carla Marchetti,
  • Claudio Maria Mastroianni,
  • Cristina Mussini,
  • Carlo Federico Perno,
  • Giuliano Rizzardini,
  • Stefano Rusconi,
  • Maria Santoro,
  • Loredana Sarmati,
  • Maurizio Zazzi,
  • Franco Maggiolo

Journal volume & issue
Vol. 196
p. 106898

Abstract

Read online

Background: Meeting the challenge of antiretroviral therapy (ART) whose efficacy can last a lifetime requires continuous updating of the virological, pharmacological, and quality of life outcomes to be pursued and a continuous review of literature data on the efficacy and tolerability of new drugs and therapeutic strategies. Methods: With the aim of identifying open questions and answers about the current controversies in modern ART, we adapted the Design Thinking methodology to the needs of the design phase of a scientific article, involving a team of experts in HIV care. Results: Five main pillars of treatment success were discussed: sustained virologic suppression over time; immunological recovery; pharmacological attributes; long-term tolerability and safety of ART; and people’s satisfaction and quality of life. The definition of the outcomes to be achieved in each thematic area and the tools to achieve them were reviewed and discussed. Conclusions: Long-term treatment success should be intended as a combination of HIV-RNA suppression, immune recovery, and high quality of life. To achieve this, the regimen should be well-tolerated, with high potency, genetic barrier, and forgiveness, and should be tailored by a person-centered perspective, based on individual needs, preferences, and therapeutic history.

Keywords